Search research articles
Contact Us
Filters
Showing results (61-70 of 300) with videos related to
Page
of 30
Sort By:
Expert Review of Cardiovascular Therapy
|
March 20, 2004
Ezetimibe: a novel option for lowering cholesterol
Michael H Davidson
Current Opinion in Lipidology
|
May 2, 2018
Clinical trials
Michael H Davidson
Expert Opinion on Pharmacotherapy
|
October 13, 2007
The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review
Michael H Davidson
The American Journal of Cardiology
|
February 20, 2007
Global risk management in patients with type 2 diabetes mellitus
Michael H Davidson
The American Journal of Managed Care
|
November 23, 2006
Differences between clinical trial efficacy and real-world effectiveness
Michael H Davidson
Arteriosclerosis, Thrombosis, and Vascular Biology
|
August 22, 2008
Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment
Michael H Davidson
Clinical Cardiology
|
September 11, 2009
Apolipoprotein measurements: is more widespread use clinically indicated?
Michael H Davidson
The American Journal of Cardiology
|
August 2, 2011
Cardiovascular effects of glucagonlike peptide-1 agonists
Michael H Davidson
Current Opinion in Lipidology
|
November 5, 2013
Omega-3 fatty acids: new insights into the pharmacology and biology of docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid
Michael H Davidson
Nature Reviews. Cardiology
|
September 11, 2013
Dyslipidaemia: PCSK9 antibodies: a dividend of the genomics revolution
Michael H Davidson
Page
of 30
Search research articles
Search
Showing results (61-70 of 300) with videos related to
Sort By:
Page
of 30
Expert Review of Cardiovascular Therapy
|
March 20, 2004
Ezetimibe: a novel option for lowering cholesterol
Michael H Davidson
Current Opinion in Lipidology
|
May 2, 2018
Clinical trials
Michael H Davidson
Expert Opinion on Pharmacotherapy
|
October 13, 2007
The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review
Michael H Davidson
The American Journal of Cardiology
|
February 20, 2007
Global risk management in patients with type 2 diabetes mellitus
Michael H Davidson
The American Journal of Managed Care
|
November 23, 2006
Differences between clinical trial efficacy and real-world effectiveness
Michael H Davidson
Arteriosclerosis, Thrombosis, and Vascular Biology
|
August 22, 2008
Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment
Michael H Davidson
Clinical Cardiology
|
September 11, 2009
Apolipoprotein measurements: is more widespread use clinically indicated?
Michael H Davidson
The American Journal of Cardiology
|
August 2, 2011
Cardiovascular effects of glucagonlike peptide-1 agonists
Michael H Davidson
Current Opinion in Lipidology
|
November 5, 2013
Omega-3 fatty acids: new insights into the pharmacology and biology of docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid
Michael H Davidson
Nature Reviews. Cardiology
|
September 11, 2013
Dyslipidaemia: PCSK9 antibodies: a dividend of the genomics revolution
Michael H Davidson
Page
of 30